Immunological Network Signature of Naïve Non-Oncogene-Addicted Non-Small Cell Lung Cancer Patients Treated with Anti-PD1 Therapy: A Pilot Study
Cancers,
Journal Year:
2025,
Volume and Issue:
17(6), P. 922 - 922
Published: March 8, 2025
Background/Objectives:
Non-small
cell
lung
cancer
(NSCLC)
patients
without
gene
driver
mutations
receive
anti-PD1
treatments
either
as
monotherapy
or
in
combination
with
chemotherapy
based
on
PD-L1
expression
tumor
tissue.
Anti-PD1
antibodies
target
various
immune
system
components,
perturbing
the
balance
between
cells
and
soluble
factors.
In
this
study,
we
identified
signatures
of
NSCLC
associated
different
clinical
outcomes
through
network
analysis.
Methods:
Twenty-seven
metastatic
were
assessed
at
baseline
for
levels
circulating
CD137+
T
(total,
CD4+,
CD8+)
via
cytofluorimetry,
along
14
checkpoints
20
cytokines
Luminex
Hierarchical
clustering
connectivity
heatmaps
executed,
analyzing
response
to
therapy
(R
vs.
NR),
performance
status
(PS
=
0
PS
>
0),
overall
survival
(OS
<
3
months
OS
months).
Results:
The
revealed
three
groups
a
significant
differential
proportion
six
(p
0.0001).
Furthermore,
pairwise
correlations
among
factors
evaluated
R
compared
lack
same
NR
vice
versa.
These
comparisons
conducted
months.
results
indicated
that
≤
exhibited
an
inflammatory-specific
signature
contrasting
conditions
characterized
by
checkpoint
molecule-based
0.05).
Conclusions:
Identifying
profiles
linked
therapy,
PS,
represents
findings
can
optimize
therapeutic
choices.
Language: Английский
Multidimensional Predictive Model of Survival Risk in Small Cell Lung Cancer Patients: A Comprehensive Analysis Based on Clinical Characteristics and Treatment Strategies
Current Problems in Surgery,
Journal Year:
2025,
Volume and Issue:
unknown, P. 101759 - 101759
Published: March 1, 2025
Language: Английский